Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867018 | 1.00 | CYP3A4 (0.43) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL4869429 | 1.00 | CYP3A4 (0.43) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL4866730 | 1.00 | CYP3A4 (0.43) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL11007092 | 0.78 | DPP4 (0.43) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL24310396 | 0.76 | CYP3A4 (0.48) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL13593671 | 0.76 | CYP3A4 (0.48) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL13164136 | 0.76 | CYP3A4 (0.48) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| Hydrochloric Acid SCHEMBL18766055 | 0.74 | MAPT (0.47) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL31292033 | 0.69 | CYP3A4 (0.36) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL12391755 | 0.67 | MAPT (0.43) | CYP3A4TSHRTDP1MAPTAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429587-B2 | Pyrrolidine derivatives as factor Xa inhibitors | GLAXO GROUP LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7282497-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2007-10-16 | — | — | US | disclosed |
| US-20070155745-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | CHAN CHUEN | 2007-07-05 | — | — | US | disclosed |
| US-20060160886-A1 | Synergistic mixtures of 6-Chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide and 4-chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide; improved oral bioavailability and pharmacokinetics | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155745-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | TFPI, F2, SERPINC1 | CYP3A4 301/4885TSHR 1908/4885TDP1 1204/4885 |
| US-20060160886-A1 | Synergistic mixtures of 6-Chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide and 4-chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide; improved oral bioavailability and pharmacokinetics | SULT1E1, SULT1A1, SULT2A1 | CYP3A4 14/4885TSHR 1289/4885TDP1 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.